Log In
BCIQ
Print this Print this
 

CPX-1

  Manage Alerts
Collapse Summary General Information
Company Jazz Pharmaceuticals plc
DescriptionFormulation of irinotecan HCl and floxuridine using CombiPlex technology
Molecular Target Topoisomerase I (TOP1)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationColorectal cancer
Indication DetailsTreat advanced colorectal cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$1,500.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/12/2016

$1,500.0M

$1,500.0M

0

Get a free BioCentury trial today